AAV Gene Therapy Analytical
Development and Quality Control

Specialized gene therapy analytical methods and QC consulting: from ATP design through ICH-compliant method validation, potency assay development, and AAV vector characterization for IND, BLA, and commercial submissions.

pharma lab

Product Quality & Compliance Excellence Commitment to
Deliver Product Quality

DES Pharma provides comprehensive analytical and quality control support across all stages of drug development. From method development to routine testing and regulatory compliance, we ensure your AAV gene therapy and biologic products meet rigorous standards for safety, efficacy, and quality.

Our analytical team has deep experience in viral vector characterization, including the specialized assays required for gene therapy: potency assays, empty/full capsid analytics, residual DNA and host cell protein testing, and ICH-compliant method lifecycle management.

🧬

AAV Gene Therapy Characterization Methods

Specialized analytical capabilities for adeno-associated virus vector quantification and quality assessment

These AAV characterization methods include empty/full capsid ratio analysis, vector genome titer (ddPCR, qPCR), and residual DNA testing. Our analytical consultants develop fit-for-purpose methods that meet FDA and EMA expectations for gene therapy IND and BLA submissions per ICH Q2(R2) and ICH Q14.

🚀 Empty/Full Capsid Ratio (AUC, AEX)
🚀 Vector Genome Titer (ddPCR / qPCR)
🚀 Potency Assay Development & Validation
🚀 Residual DNA & Host Cell Protein Testing
🚀 Transmission Electron Microscopy (TEM)
🚀 DLS / SEC Particle Characterization
🚀 Capsid Protein Identity (SDS-PAGE, WB)
🚀 Transduction Efficiency & In-Vitro Potency

Guiding Analytical Strategy Through Data Our AD & QC Frameworks
for Gene Therapy

We build structured frameworks that uphold the core principles of analytical development and quality control, calibrated for the unique complexity of AAV and viral vector products.

Analytical Development (AD)

High Structure, High ROI

Analytical Development provides scientific expertise to support key decision points related to AAV gene therapy product safety and efficacy across all phases of development.

Quality Control (QC)

Driving Data-Backed Decisions

Quality Control ensures AAV gene therapy products are consistently safe, effective, and high-quality by establishing a clear testing system aligned with global regulations.

AAV-Specific Analytical Methods Reference Critical Quality Attributes
& Testing Methods

CQA / Attribute Recommended Method(s) Regulatory Reference Type
Vector Genome Titer ddPCR, qPCR (ITR or transgene-based) FDA CBER Guidance 2020; ICH Q2(R2) CQA
Empty/Full Capsid Ratio AUC, AEX-HPLC, TEM, ELISA FDA Gene Therapy Guidance 2021 CQA
Capsid Titer (Physical Particles) ELISA (capsid), MALS, DLS USP <788>; ICH Q6B CQA
Potency (Transduction) In vitro transduction assay, luciferase reporter, FACS ICH Q6B; FDA Potency Guidance CQA
Purity: HCP Host Cell Protein ELISA (process-specific) ICH Q6B; USP <1132> Purity
Purity: Residual DNA qPCR (host cell DNA), ThunderBird assay FDA 21 CFR 610; ICH Q5A Purity
Identity SDS-PAGE / Western Blot, VP1/VP2/VP3 ratio ICH Q6B; USP <1084> Identity
Sterility & Mycoplasma USP <71> sterility; PCR mycoplasma 21 CFR 610.12; ICH Q5A Safety
Adventitious Agents Broad-range PCR, cell-based assays, in-vivo testing ICH Q5A(R2); FDA CBER Guidance Safety

Gene Therapy Analytical Expertise Deep Expertise in AAV Vector Characterization

Gene therapy analytical development requires more than standard biologic methods. AAV vectors present unique characterization challenges: quantifying both physical and functional particles, assessing capsid integrity and empty/full ratio, and developing potency assays that are clinically relevant, reproducible, and transfer-ready.

Our team has built and validated AAV-specific analytical panels across serotypes, supporting programs from early pre-clinical qualification through ICH-compliant BLA method validation packages. We align every method to the Analytical Target Profile (ATP) and support regulatory submissions to FDA CBER and EMA using current guidelines for gene therapy products.

From selecting the right ddPCR approach for vector genome titer to developing a robust cell-based transduction potency assay that passes ICH Q2(R2) validation, DES Pharma delivers analytical solutions that hold up through tech transfer and regulatory scrutiny.

Potency Assay Development & Validation

Cell-based transduction assays, reporter systems, FACS-based quantification: designed for robustness, transferability, and ICH Q2(R2) / ICH Q6B compliance

Empty/Full Capsid Ratio Analytics

AUC, AEX-HPLC, and TEM methods for capsid occupancy: critical CQA for AAV efficacy and safety per FDA CBER gene therapy guidance

Method Lifecycle Management

ATP-driven approach aligned with ICH Q14 and USP: from development through routine QC, tech transfer, and post-approval change management

Specification Development & Justification

Science- and risk-based specification setting for release and stability, with regulatory justification documents aligned with ICH Q6B and FDA expectations

Analytical Method Tech Transfer

Structured transfer protocols, acceptance criteria, and comparative testing packages for CDMO and QC laboratory transitions

Full-Spectrum Analytical Services AD & QC Services for
Gene Therapy Programs

Comprehensive analytical and quality control consulting across
the entire AAV gene therapy development lifecycle.

 

Analytical Development (AD) Services

Quality Control (QC) Services

Get Started Advance Your AAV Analytical Program with Confidence

Build robust, regulatory-ready analytical methods for your gene therapy product today.